FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4376132259> ?p ?o ?g. }

• W4376132259 endingPage "1158" @default.
• W4376132259 startingPage "1143" @default.
• W4376132259 abstract "ABSTRACTABSTRACTIntroduction The human respiratory syncytial virus (hRSV) is the leading cause of respiratory infections in children, older adults, and patients with comorbidities. Since the hRSV discovery, multiple efforts have been made to generate therapies that control the devastating effects on the population at risk in winter.Areas covered This article describes the development of different drugs and treatments approved for use in the risk-population against hRSV infection. In addition, an exhaustive bibliographical review is presented here describing new candidate molecules under evaluation and showing promising results in different assays in animal models and clinical studies. Additionally, we highlight antiviral molecules, monoclonal antibodies, and nanobodies among the new candidate treatments.Expert opinion hRSV is a major burden for the health systems, promoting their collapse worldwide. Therefore, developing new therapies is an essential goal to decrease hospitalization rates caused by hRSV infection in high-risk populations. For this, injecting resources and exploring new targets in addition to the F protein is an interesting alternative to achieve this goal.KEYWORDS: Human respiratory syncytial virusantibodiestreatmentsprophylaxisnanobodies AcknowledgmentsWe thank Biorender for making their templates available online, which we employed to construct the figure in this article.Article highlights The currently approved therapies against hRSV are only palivizumab and Ribavirin.Nirsevimab is a new promising humanized hRSV-specific monoclonal antibody.Nanobodies, such as ALX-0171 against hRSV, are considered promising technology for therapy design against this virus.Most hRSV therapies, like drugs and antibodies, target the F protein to inhibit the fusion of the virus to the host cell.Declaration of interestThe authors declare the following possible conflict of interest: Patent application (September 2018) entitled: Monoclonal Antibody specific against the antigen N of the Human Respiratory Syncytial Virus (VRSH), useful for the treatment of infection, its detection, and diagnosis. PCT/CL2018/050079.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Additional informationFundingThis work was supported by funding from the Millennium Institute on Immunology and Immunotherapy ANID ACE 210015 (CN09_016/ICN 2021_045; former P09/016-F, AMK); CONICYT/FONDECYT grants # 1231866 and PAI SA77210051 (JAS); #1190830 and 1231851 (AMK) and Biomedical Research Consortium CTU06 (AMK). This work was also supported by the Regional Government of Antofagasta through the Innovation Fund for Competitiveness FICR 2017 (BIP Code: 30488811-0)." @default.
• W4376132259 created "2023-05-12" @default.
• W4376132259 creator A5034528189 @default.
• W4376132259 creator A5045446127 @default.
• W4376132259 creator A5046302587 @default.
• W4376132259 creator A5074078236 @default.
• W4376132259 creator A5083899187 @default.
• W4376132259 date "2023-05-16" @default.
• W4376132259 modified "2023-10-04" @default.
• W4376132259 title "Current and emerging pharmacological treatments for respiratory syncytial virus infection in high-risk infants" @default.
• W4376132259 cites W1264104737 @default.
• W4376132259 cites W1527372192 @default.
• W4376132259 cites W1542698852 @default.
• W4376132259 cites W1580407891 @default.
• W4376132259 cites W1590105742 @default.
• W4376132259 cites W1962254654 @default.
• W4376132259 cites W1966822148 @default.
• W4376132259 cites W1970284010 @default.
• W4376132259 cites W1980682746 @default.
• W4376132259 cites W1985099748 @default.
• W4376132259 cites W1985729869 @default.
• W4376132259 cites W1992959504 @default.
• W4376132259 cites W2002199584 @default.
• W4376132259 cites W2002985673 @default.
• W4376132259 cites W2003652041 @default.
• W4376132259 cites W2004663239 @default.
• W4376132259 cites W2010107509 @default.
• W4376132259 cites W2010506716 @default.
• W4376132259 cites W2015537895 @default.
• W4376132259 cites W2015576538 @default.
• W4376132259 cites W2019706667 @default.
• W4376132259 cites W2020378082 @default.
• W4376132259 cites W2036186137 @default.
• W4376132259 cites W2037758725 @default.
• W4376132259 cites W2042439545 @default.
• W4376132259 cites W2047432734 @default.
• W4376132259 cites W2051096704 @default.
• W4376132259 cites W2052035353 @default.
• W4376132259 cites W2053319140 @default.
• W4376132259 cites W2072067155 @default.
• W4376132259 cites W2074884080 @default.
• W4376132259 cites W2077507635 @default.
• W4376132259 cites W2089505575 @default.
• W4376132259 cites W2093529351 @default.
• W4376132259 cites W2094048920 @default.
• W4376132259 cites W2096922886 @default.
• W4376132259 cites W2099090318 @default.
• W4376132259 cites W2099983228 @default.
• W4376132259 cites W2110547872 @default.
• W4376132259 cites W2117117816 @default.
• W4376132259 cites W2117608592 @default.
• W4376132259 cites W2120949068 @default.
• W4376132259 cites W2122297292 @default.
• W4376132259 cites W2123817481 @default.
• W4376132259 cites W2124528183 @default.
• W4376132259 cites W2131179865 @default.
• W4376132259 cites W2134517216 @default.
• W4376132259 cites W2139399379 @default.
• W4376132259 cites W2141468679 @default.
• W4376132259 cites W2142073032 @default.
• W4376132259 cites W2148090354 @default.
• W4376132259 cites W2154028520 @default.
• W4376132259 cites W2156732206 @default.
• W4376132259 cites W2159725619 @default.
• W4376132259 cites W2163513330 @default.
• W4376132259 cites W2166468034 @default.
• W4376132259 cites W2168130828 @default.
• W4376132259 cites W2169296242 @default.
• W4376132259 cites W2190008856 @default.
• W4376132259 cites W2190300929 @default.
• W4376132259 cites W2263858093 @default.
• W4376132259 cites W2328116798 @default.
• W4376132259 cites W2330176961 @default.
• W4376132259 cites W2332532573 @default.
• W4376132259 cites W2397498130 @default.
• W4376132259 cites W2415091484 @default.
• W4376132259 cites W2465525754 @default.
• W4376132259 cites W251016307 @default.
• W4376132259 cites W2523480234 @default.
• W4376132259 cites W2601936374 @default.
• W4376132259 cites W2611361909 @default.
• W4376132259 cites W2659751330 @default.
• W4376132259 cites W2738340469 @default.
• W4376132259 cites W2754710698 @default.
• W4376132259 cites W2761063128 @default.
• W4376132259 cites W2785431220 @default.
• W4376132259 cites W2789240485 @default.
• W4376132259 cites W2791165666 @default.
• W4376132259 cites W2794936122 @default.
• W4376132259 cites W2799481379 @default.
• W4376132259 cites W2801372131 @default.
• W4376132259 cites W2802389975 @default.
• W4376132259 cites W2802452703 @default.
• W4376132259 cites W2802776155 @default.
• W4376132259 cites W2807193652 @default.
• W4376132259 cites W2898372989 @default.
• W4376132259 cites W2899323717 @default.
• W4376132259 cites W2904771838 @default.

• next